Key Takeaways:
- Masimo (MASI, Financial) reported a Q4 revenue increase of 9.4%, exceeding analyst expectations.
- Despite the revenue boost, Masimo's stock has seen a decline of 7.9% post-earnings report.
- Analysts predict an average price target of $195.70, signaling a potential upside.
Masimo Corp (MASI), renowned for its pioneering noninvasive patient monitoring technologies, has recorded an impressive 9.4% boost in Q4 revenue, reaching a total of $600.7 million. This figure not only highlights the company's robust performance but also exceeds analyst projections by 1.5%. However, in an unexpected turn, the stock has experienced a 7.9% decline since the earnings announcement, currently trading at $155.78.
Wall Street Analysts Forecast
The one-year price projections from 8 analysts position Masimo Corp (MASI, Financial) with an average target price of $195.70. This forecast sits between a high estimate of $215.00 and a low of $170.58, reflecting an anticipated upside of 23.89% from the present price of $157.96. Investors seeking more comprehensive estimate data can visit the Masimo Corp (MASI) Forecast page.
Furthermore, the consensus recommendation from 9 brokerage firms rates Masimo Corp (MASI, Financial) at an average of 2.0, suggesting an "Outperform" status. The rating scale, ranging from 1 to 5, designates 1 as a Strong Buy and 5 as a Sell, underscoring the positive sentiment among analysts.
Analyzing the company's valuation through GuruFocus metrics, the estimated GF Value for Masimo Corp (MASI, Financial) in the coming year is pegged at $126.91. This suggests a potential downside of 19.66% from the current stock price of $157.96. The GF Value represents GuruFocus' fair value estimate, derived from historical trading multiples, prior business growth, and future performance predictions. Investors can explore detailed data on the Masimo Corp (MASI) Summary page.
